Stockscreener 앱 받기
1.66%
시간 외 거래:
Pfizer Inc 주식(PFE)의 최신 뉴스
GSK resolves patent lawsuit against Pfizer over RSV vaccines - The Mighty 790 KFGO
Healthcare: Policy Uncertainty Is Countered by Interest in Defensive Stocks - Morningstar
News | Pfizer sells San Diego biotech office campus in top-dollar deal - CoStar
Pfizer, Inc. (PFE) Stock Forecasts - Yahoo Finance
Biosimilars Market Deep Research 2025-2032 | Amgen Inc., Pfizer - openPR.com
Better Beaten-Down Stock to Buy: Pfizer Vs. Moderna - Nasdaq
Atorvastatin Api Market is Set to Experience a Revolutionary Growth | Pfizer Inc.,Merck & Co.,Novartis AG - openPR.com
Is Pfizer Stock a Buy? - Nasdaq
Esophageal Cancer Market research 2024-2032 Featuring AstraZeneca, Takeda, Pfizer, Novartis, Amgen, Bristol-Myers Squibb, Eli Lily and Co, Sanofi, AbbVie, and GSK - Yahoo Finance
Eye Health Supplements Market Growth in Future Scope 2025-2032 | - openPR.com
Request for Proposals: Pfizer Quality Improvement Grant Program (Italy) - fundsforNGOs
Pfizer (PFE) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance
UK's Health Agency Endorses Pfizer's Blood Cancer Combo Therapy As First For Untreated Hodgkin Lymphoma Patients - Benzinga
Proxy adviser ISS recommends against Pfizer executive pay proposal - Reuters
Potential Stock Woe Ahead as Pfizer (PFE) Riles Donald Trump - Yahoo Finance
3 Stocks Leading Healthcare’s Comeback as Wall Street Turns Defensive - Investing.com
Pfizer stock hits 52-week low at $24.42 amid market shifts - Investing.com Australia
Proxy adviser ISS recommends Pfizer shareholders reject executive compensation proposal - MarketScreener
Proxy adviser ISS recommends Pfizer shareholders to vote against CEO compensation - MarketScreener
Antibacterial Drugs Market Is Booming So Rapidly 2025-2032 - openPR.com
Exclusive: Mikael Dolsten shares his post-Pfizer plans, including advising an AI unicorn with pharma dreams - Endpoints News
PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo - TradingView
Pfizer secures expanded EC authorisation for Abrysvo vaccine - World Pharmaceutical Frontiers
Pfizer Crosses Above 7% Yield Territory - Forbes
Pfizer wins label expansion for RSV shot in EU (PFE:NYSE) - Seeking Alpha
Pfizer, Merck Lose Appeal To Patent Cancer Drug Dosage - Law360
Pfizer (NYSE:PFE) Expands RSV Vaccine Use In Europe Amid 3% Share Price Dip - simplywall.st
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Global markets live: Tesla, Chevron, Pfizer, Michelin, Toyota… - MarketScreener
Injectable Drugs Market to Witness Massive Growth by 2032 | - openPR.com
Is Pfizer Inc. (PFE) the Most Undervalued Healthcare Stock to Buy According to Analysts? - Yahoo Finance
Flagship Pioneering Agreement With Pioneering Medicines & Pfizer To Discover Potential Novel, Selective Inhibitors For Autoimmune Disease - MarketScreener
Former Pfizer CSO Mikael Dolsten on writing his next chapter, embracing AI and asking the ‘big questions’ - PharmaVoice
Pfizer: extension of indication for RSV vaccine - MarketScreener
Major Breakthrough: Pfizer Teams With Flagship to Develop AI-Driven Autoimmune Treatments - Stock Titan
Pfizer’s RSV vaccine wins expanded approval in EU, gaining edge over GSK - Yahoo Finance
Pfizer Says European Commission Approves Abrysvo RSV Vaccine for Adults - MarketScreener
European Commission approves Pfizer's RSV vaccine for adults at increased risk of disease - Reuters
to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease - Business Wire
Pfizer COVID-19 Bombshell Puts 2020 Election Into Context - The Daily Signal
Inflammatory Myositis Market on Track for Major Expansion by 2034, According to DelveInsight | CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharma, Pfizer, Horizon Therapeutics - Barchart.com
Is Trending Stock Pfizer Inc. (PFE) a Buy Now? - Yahoo Finance
Pfizer: Looks Better Than Most, But I Can't Eat Relative Returns - Seeking Alpha
Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again - insights.citeline.com
Pfizer Inc. (NYSE:PFE) Shares Sold by Wellington Management Group LLP - MarketBeat
Pfizer Inc. - Britannica
Pfizer Inc. (PFE): Among Blue Chip Stocks to Invest in at 52-Week Lows - Insider Monkey
Pfizer and other pandemic favorites in focus as FDA’s top vaccine regulator resigns - Seeking Alpha
What Does the Market Think About Pfizer? - Benzinga
Pfizer: Shares Stabilize At $25 As Institutions Begin To Load Up (Rating Upgrade) - Seeking Alpha
Minoxidil Market Set to Witness Significant Growth by 2025-2032 - openPR
Pfizer leader who launched Covid vaccine gives small pharma a try - The Business Journals
Senator Slams Pfizer (PFE) for “Biggest Tax-Dodging Scheme in Pharma History” - markets.businessinsider.com
0.45%
0.24%
자본화:
|
볼륨(24시간):